What's Hot in Hematology/Oncology

“JUST IN: DeLLphi-305 study met its primary endpoint of overall survival combining tarlatamab (DLL3 BiTE) with PDL1 inhibitor Durvalumab as maintenance after 1L chemotherapy for extensive-stage small cell lung cancer !”

“Just one word - starlatamab! A star was born last year at #ASCO25 and looks like now found a steady partner in durvalumab!”

“🚨 Landmark development in ES-SCLC! Phase 3 DeLLphi-305 has shown a statistically significant and clinically meaningful OS benefit with tarlatamab (IMDELLTRA) + durvalumab versus durvalumab alone as 1L maintenance after platinum–etoposide + durvalumab. PFS and ORR also improved. A potentially important new chapter in ES-SCLC maintenance therapy.”

“SWOG/NRG S1914: In patients with high-risk T1–T3N0M0 early-stage NSCLC who were medically inoperable or declined surgery, adding peri-SBRT atezolizumab did not improve PFS or OS and increased toxicity.”

“Report @JTOonline describes mechanisms of acquired resistance to 1L lazertinib in EGFR mutant NSCLC from phase 3 LASER301 trial.”

“Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer Great review👇”

“5/ @ilyassahinMD on alcohol and breast cancer:”

“the sobering news is the all time high oral drug price, set at $480,000/year, $663/pill.”

“Can adding hypofrac, adaptive RT to SOC systemic improve outcomes in GEJ/esoph adeno?”

“Exercise improved QoL for patients on ADT for #prostatecancer & it costs less per QALY than most cancer drugs the NHS funds”

“the real question is not cystectomy vs preservation — it is who can preserve the bladder without compromising cure.”

“✨ In high-risk localized #ProstateCancer, the question is no longer simply whether to use ADT — but who needs it, for how long, and who should receive more. Excellent #IUCS26 discussion by @alison_tree on integrating loco-regional and systemic approaches. 🔵 STAMPEDE / abiraterone and ENZARAD / enzalutamide reinforce the role of systemic intensification in selected higher-risk patients, including cN1 disease. 🔵 In PROTEUS, perioperative apalutamide + ADT improved pathological response: • pCR/MRD: 8.9% vs 1.0% • Fewer positive surgical margins • 5-year MFS: 78.2% vs 73.5% in the data presented But the message is not “more treatment for everyone.” The real questions are: ➡️ Who can avoid ADT? ➡️ Who needs standard or longer-course ADT? ➡️ Who derives enough absolute benefit to justify AR-pathway intensification? 🎯 Clinical takeaway: localized high-risk prostate cancer is moving toward risk-adapted selective intensification, balancing disease control against the long-term burden of systemic therapy.”

“precision oncology in RCC is moving beyond static single biomarkers toward multimodal, longitudinal assessment — tissue, ctDNA, serum markers, imaging and tumor biology — matched to the right clinical question.”

“👏 excellent - looking forward to seeing data! Arlo-cel (GPRC5D CAR-T) hopefully en route to approval someday soon based on this. Note that arlo-cel works the same with or without prior BCMA (great work led by @SusanBal9 et al), but this trial specifically for BCMA-exposed.”

“HR myeloma is a marathon, not a sprint. With extended MUKnine course, median PFS will be over SIX YEARS (!) in ultra-HR MM without BsAbs or CAR-T 👏”

“Samples from the IFM2017-03 phase 3 trial show an inflammatory marrow state (NF-kB+ monocytes, low NK CD16) linked to daratumumab-lenalidomide resistance in MM.”

“Daratumumab finds its targets better when CELMoDs have already been there.”

“Progressive multifocal leukoencephalopathy following bispecific antibody therapy in multiple myeloma: a case series”

“The accepted definition by the FDA currently does not accept molecular relapse or change in therapy (in the absence of morphologic relapse or primary failure of induction phase therapy) as events although these are considered as important events in clinical Practice.”